Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers compared the demographics of participants in randomized controlled trials for antiretrovirals with the global HIV population.
Tenofovir alafenamide is an updated version of tenofovir disoproxil fumarate that is tied to better bone and kidney health.
The observation that there have been Covid-19 infections in HIV+ persons on TDF/TAF argues against a complete protection from these agents.
Studies have found that weight gain is common after people with HIV begin an antiretroviral in this class.
Newer drug classes are tied to a higher risk of weight gain, which is more likely to occur among Black women in particular.
Switching to new tenofovir tied to improved bone health in older people with HIV
Both Truvada and Descovy are highly effective and safe for most people taking PrEP, but the newer option has more cost barriers.
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
Learn about the differences between these two HIV prevention options.
Future research should examine how particular combinations of antiretrovirals contribute to weight gain, according to one expert.
Participants entered the study taking tenofovir disoproxil fumarate, and some were switched to a regimen including tenofovir alafenamide.
The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.
However, serious kidney problems and bone fractures were rare among people taking either Descovy or Truvada for HIV prevention.
This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.